Clinical trials
Growth Hormone Treatment clinical trials
Below are recruiting growth hormone treatment clinical trials, each written for real people, not researchers. We’re tracking 50 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06448195RecruitingPhase 4
Growth Hormone for Fatty Liver After Pituitary Surgery
This trial tests whether growth hormone therapy can improve liver health and metabolic function in people who have fatty liver after pituitary tumor surgery. It is for adults with growth hormone deficiency who have excess fat in their liver.
ShanghaiAges 18–60 - NCT06037473Recruiting
PEG growth hormone for short stature in children
This trial tests if a long-acting growth hormone (PEGylated GH) helps children with various causes of short stature grow taller. It may be an option if your child has a condition like growth hormone deficiency, Turner syndrome, or idiopathic short stature.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT07333521Recruiting
Body composition in kids on growth hormone
This study looks at how growth hormone treatment affects body composition (fat and muscle) in children with growth hormone deficiency. It may help doctors better understand and monitor treatment effects.
ParisAges 3–17 - NCT05355272RecruitingPhase 2
Growth hormone treatment for Gulf War illness with low growth hormone
This Phase 2 study tests whether replacing growth hormone can improve symptoms in veterans with Gulf War Illness and adult growth hormone deficiency. It also checks that the treatment is safe for people with stable medications and hormone regimens.
Houston, TexasAges 18–64 - NCT04867317RecruitingPhase 3
Growth hormone treatment for veterans with mild TBI and deficiency
This Phase 3 study tests whether replacing growth hormone in veterans with mild traumatic brain injury (mTBI) and low adult growth hormone can improve quality of life. If you qualify, you’ll be screened with hormone blood tests and memory/mental health checks before starting treatment.
Birmingham, AlabamaAges 21–55 - NCT06803589RecruitingEarly Phase 1
Growth hormone for hard-to-treat stomach paralysis
This study tests if growth hormone can help people with long-term stomach paralysis (gastroparesis) that hasn't improved with standard care. It looks at whether the treatment reduces symptoms like nausea and feeling full too quickly.
Phoenix, ArizonaAges 18–65 - NCT07016802RecruitingPhase 1
Study of GenSci134 for growth hormone deficiency
This trial tests a new growth hormone treatment called GenSci134 in healthy adults and adults with growth hormone deficiency (AGHD). The goal is to see if it is safe and effective for people who need growth hormone replacement.
Beijing, Beijing MunicipalityAges 18–70 - NCT07553351RecruitingPhase 3
Growth hormone treatment for children with growth hormone deficiency
This trial tests a new growth hormone medicine (GB06) for children whose bodies don't make enough growth hormone naturally. The study will see if this treatment helps children grow taller over time.
Chengdu, SichuanAges 3–11 - NCT06948214RecruitingPhase 3
LUM-201 for growth hormone deficiency in children
This trial tests a new medicine called LUM-201 for children who haven't grown enough because their bodies don't make enough growth hormone. It aims to help kids who haven't been treated before and are still at an early stage of puberty.
Birmingham, AlabamaAges 3–11 - NCT06110910Recruiting
Growth hormone study for children with short stature
This study tests if growth hormone can safely help children who are shorter than average for their age and gender. It is for children with certain conditions that cause short stature.
Wuhan, HubeiAges 2 years+ - NCT06668805RecruitingPhase 2
Testing vosoritide for children with Noonan syndrome and slow growth
This study tests a medication called vosoritide for children with Noonan syndrome who are still growing slowly despite using human growth hormone. The goal is to see if vosoritide can help them grow taller.
Los Angeles, CaliforniaAges 3–11 - NCT05447208RecruitingPhase 3
Testing growth hormone to improve embryo chromosome screening results
This Phase 3 study tests whether growth hormone given during IVF can improve the chance of getting embryos with the “right” number of chromosomes, which is checked by PGT-A. It may help some people who are 38 or older planning chromosome testing of embryos.
Shanghai, Shanghai MunicipalityAges 38 years+ - NCT07551804RecruitingPhase 2
Growth hormone replacement therapy safety and effectiveness study
This study tests a new injectable growth hormone treatment for adults whose bodies don't produce enough growth hormone naturally. Researchers will measure how safe it is, how your body processes it, and whether it helps you feel better and function more normally.
BeijingAges 18–80 - NCT03972345Enrolling by invitation
Study on how sticking to growth hormone affects near adult height
This study looks at whether consistently taking growth hormone (Norditropin) helps children reach a height goal by “near final height.” It focuses on children who are short due to growth hormone deficiency or born small for gestational age.
UlmAges birth–15 years - NCT05144035RecruitingPhase 4
Early growth-hormone treatment for small baby’s brain development
This study tests whether starting a growth hormone treatment early helps a baby’s thinking and learning development. It is for babies who are small for their gestational age and show delays on a developmental screening test.
Wuhan, WuhanAges 6 months–2 years - NCT06109935Enrolling by invitation
Long-term study of Sogroya for children with growth hormone deficiency
This trial is looking at how well Sogroya® (a growth hormone medicine) works when used for a long time in children with short stature caused by growth hormone deficiency. The goal is to see if it helps them grow taller safely.
AichiAges birth–18 years - NCT06542809Recruiting
Growth hormone medicine change survey for kids
This survey asks children and teens currently using daily growth hormone shots if they would like to switch to a longer-acting medicine that requires fewer injections. Your answers will help doctors understand patient preferences.
Brussels, Woluwe-saint-lambertAges 1 day–18 years - NCT05796440Enrolling by invitationPhase 2
Long-term safety study of LUM-201 in children with growth hormone deficiency
This trial checks the long-term safety of LUM-201 in children who have idiopathic growth hormone deficiency and already completed an earlier LUM-201 study. If you previously took LUM-201 and are allowed to continue, the study may help your care team monitor ongoing effects over time.
Iowa City, IowaAges 5–14 - NCT05718570Enrolling by invitation
Long-term follow-up for adults taking Sogroya for growth hormone deficiency
This study follows adults with growth hormone deficiency who start (or have started) Sogroya to learn about its long-term safety. It does not change your treatment—it mainly checks for side effects and health outcomes over time.
Phoenix, ArizonaAges 18 years+ - NCT06709040Enrolling by invitation
Long-term safety of somapacitan in children with growth hormone deficiency
This study is watching children who are already taking somapacitan (a growth hormone injection) to see if it is safe over a long time. It collects information about growth and any side effects.
Glasgow, ScotlandAges Up to 18 years - NCT04798690Recruiting
Long-term growth injections for short children
This trial studies the long-term safety and effectiveness of Growtropin®-II, a growth hormone–type injection, in children who are short due to certain causes. It may help your child’s growth over time, while also closely tracking side effects.
Seoul, Seodaemun-guAges 2 years+ - NCT06952998RecruitingPhase 4
Platelet-rich plasma for diabetic foot ulcers with artery disease
This trial tests if a special treatment made from your own blood (platelet-rich plasma) can help heal foot ulcers in people with diabetes and poor circulation in their legs. The goal is to see if it improves wound healing compared to standard care.
Bilbao, BizkaiaAges 18 years+ - NCT07221851RecruitingPhase 3
Weekly vs daily growth hormone for short stature in children
This trial tests a weekly growth hormone injection (lonapegsomatropin) compared to the standard daily growth hormone shot in children with short stature due to certain conditions. It aims to see if the weekly shot works as well or better and is safe.
Palo Alto, CaliforniaAges 2–17 - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+
Hear when a new Growth Hormone Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for growth hormone treatment?
- Yes. Clin2 currently lists 50 recruiting growth hormone treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a growth hormone treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a growth hormone treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.